195 related articles for article (PubMed ID: 36917021)
1. Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
3. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
Malouf GG; Ali SM; Wang K; Balasubramanian S; Ross JS; Miller VA; Stephens PJ; Khayat D; Pal SK; Su X; Sircar K; Tamboli P; Jonasch E; Tannir NM; Wood CG; Karam JA
Eur Urol; 2016 Aug; 70(2):348-57. PubMed ID: 26895810
[TBL] [Abstract][Full Text] [Related]
4. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.
Bratslavsky G; Gleicher S; Jacob JM; Sanford TH; Shapiro O; Bourboulia D; Gay LM; Andrea Elvin J; Vergilio JA; Suh J; Ramkissoon S; Severson EA; Killian JK; Schrock AB; Chung JH; Miller VA; Mollapour M; Ross JS
Urol Oncol; 2021 Jun; 39(6):367.e1-367.e5. PubMed ID: 33775530
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
7. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS
Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
Wang J; Xi Z; Xi J; Zhang H; Li J; Xia Y; Yi Y
Cancer Cell Int; 2018; 18():159. PubMed ID: 30349421
[TBL] [Abstract][Full Text] [Related]
12. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
[TBL] [Abstract][Full Text] [Related]
13. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
15. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
16. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
17. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract][Full Text] [Related]
18. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
20. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
